13

“If you go to the London Declaration, then several pharmaceutical companies have engaged at different levels and for different diseases and some are engaged in several diseases. Perhaps there is one disease where several companies look at and where there is more a synergy than a competition. (…) it would probably be an agreement on where each one will do what [is needed] to make sure that it is an optimization of investments.”—Priv1